|
See related Vidaza powd for inj information |
|
|
|
製造商 |
Celgene |
|
代理/經銷商 |
Purzer |
|
成份 |
Azacitidine |
|
適應症 |
Treatment of myelodysplastic syndrome subtypes: Refractory anemia or refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation & chronic myelomonocytic leukemia. |
|
用量 |
75 mg/m2 SC/IV daily for 7 days. Cycles should be repeated every 4 weeks. Dose may be increased to 100 mg/m2 if no effect is seen after 2 treatment cycles & if no toxicity other than nausea & vomiting has occurred. |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
Hypersensitivity to azacitidine or mannitol. Advanced malignant hepatic tumors. |
|
注意事項 |
Perform complete blood count. Liver disease. Renal impairment. Pregnancy & lactation. |
|
不良反應 |
Nausea, anemia, thrombocytopenia, vomiting, pyrexia, leukopenia, diarrhea, fatigue, injection site erythema, constipation, neutropenia, ecchymosis.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
|
|
Manufacturer: |
Celgene |
|
Distributor: |
Purzer
|
|
|
|
